Fernando L Pagan
Georgetown University · Georgetown Univeristy
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fernando L Pagan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04002674 · Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy BodiesGeorgetown University · completed · Dementia With Lewy Bodies · principal investigator
- Ph2NCT03996460 · K0706 for Patients Diagnosed With Dementia With Lewy BodiesGeorgetown University · terminated · Dementia With Lewy Bodies · principal investigator
- Ph2NCT03888222 · Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy BodiesGeorgetown University · completed · Dementia With Lewy Bodies · principal investigator
- Ph2NCT02954978 · Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseGeorgetown University · completed · Parkinson Disease, Parkinsons Disease With Dementia · principal investigator
- Ph4NCT01497652 · A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyGeorgetown University · completed · Parkinson's Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:56 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.JAMA Neurol · 2020142 citationsRCR 7.5
- Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.Pharmacol Res Perspect · 201990 citationsRCR 4.1
- Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor.Tremor Other Hyperkinet Mov (N Y) · 202060 citationsRCR 4.9
- 53 citationsRCR 3.4
- Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodies.Parkinsonism Relat Disord · 20251 citationsRCR 0.3